Mesenchymal Stromal Cell Therapy For The Treatment Of Acute Respiratory Distress Syndrome

Summary

This is an open label, dose escalating safety study of the advanced therapy investigational medicinal product (ATIMP) KI-MSC-PL-205, where patients diagnosed with SARS-CoV-2-induced severe acute respiratory distress syndrome (ARDS), according to the Berlin Definition, and who are on respirator/ventilator (used synonymously in this protocol) support due to respiratory insufficiency with or without concomitant circulatory problems, will be included and treated with a single dose of KI-MSC-PL-205.

Timeline

Start

2020-06-17

Primary completion

2021-01-30

Completion

2026-04-15

Drugs

Indications